🟢 ABSI is trading 19.9% up today after positive Phase 1 hair-loss data

ABSI is trading at $8.88 (19.9%) up today after releasing positive interim Phase 1 data for its hair-loss antibody ABS-201.

• The company reported favorable safety and pharmacokinetic results from the single ascending dose cohorts in its HEADLINE trial.
• The data supports a long dosing interval and allows the study to advance to multiple ascending dose cohorts.
• Traders are reacting to the potential of ABS-201 as a novel hair-loss treatment, driving strong pre-market demand.